Featured Research

from universities, journals, and other organizations

Athletes at risk: New, inexpensive test for 'sudden death syndrome'

Date:
April 22, 2011
Source:
American Friends of Tel Aviv University
Summary:
A cardiologist has developed a new, inexpensive test for "sudden death syndrome" that's already being used by doctors in America -- and it can be done at the patient's bedside.

When a high school athlete drops dead, the rare but fatal condition called "sudden death syndrome" dominates the headlines. For reasons that remain a mystery to scientists, some young athletes -- especially young males -- begin to experience an unusual heart arrhythmia. With over-exertion, their hearts stop pumping, leading to sudden death.

Until now, screening for the hard-to-detect syndrome has been prohibitively expensive. But cardiologist Dr. Sami Viskin of Tel Aviv University's Sackler Faculty of Medicine has developed a new test that's already being used by doctors in America -- and may have already saved lives.

The "Viskin Test" is based on the researcher's discovery that almost imperceptible abnormalities between normal and at-risk patients could be suddenly be made more visible using a simple bedside test that requires a subject to suddenly stand up. When standing, at-risk patients will experience a measurable difference in a portion of their heart rate called the QT interval. The difference can be detected by an electrocardiogram (ECG).

Dr. Viskin described his research in a recent issue of the Journal of the American College of Cardiology.

The long and short of the QT test

"Current screening methods offer no real therapeutic value, because very few people who experience arrhythmias, up to 20 percent of the population, will ever die from sudden death," Dr. Viskin says. "Moreover, there is such a significant overlap between what's normal and abnormal on an ECG that we need additional screening parameters. This test, when done on people with strong symptoms, can really give us doctors a yardstick to compare those at risk for sudden death syndrome to those who would otherwise go on to live a healthy life."

According to Dr. Viskin, the QT interval shortens when the heart rate accelerates, but this response is not instantaneous. In the study, he tested whether sudden changes in a body as it stands up would reveal an abnormally prolonged QT interval patients with long QT syndrome (LQTS), the most common cause of sudden death. Those affected with LQTS have a normal heart structure but have problems in the electrical discharge in the heart -- they have trouble "recharging" after these sudden changes.

Young people who suddenly faint for no reason, have dizzy spells or have a family history of LQTS are very good potential candidates for this new test, Dr. Viskin says.

A warning for immediate intervention

In the study that led to the "Viskin Test," Dr. Viskin assessed 68 patients with LQTS and 82 control subjects who all underwent a baseline ECG while resting in the supine position. They were then asked to get up quickly and stand still during continuous ECG recording. The QT interval was then studied over various time periods.

In response to brisk standing, both the LQTS patients and the control subjects showed similar heart rate acceleration. But Dr. Viskin discovered that the QT interval in LQTS patients increased significantly.

"This test adds diagnostic value. And the beauty of the test," Dr. Viskin adds, "is that it's easily done at the patient's bedside. It eliminates the need for more expensive IV tests and more strenuous exercise tests."

He adds that, while untreated LQTS can be life-threatening, the therapies to treat it can be very effective.


Story Source:

The above story is based on materials provided by American Friends of Tel Aviv University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Michael H. Gollob, Calum J. Redpath, Jason D. Roberts. The Short QT Syndrome. Journal of the American College of Cardiology, 2011; 57 (7): 802 DOI: 10.1016/j.jacc.2010.09.048

Cite This Page:

American Friends of Tel Aviv University. "Athletes at risk: New, inexpensive test for 'sudden death syndrome'." ScienceDaily. ScienceDaily, 22 April 2011. <www.sciencedaily.com/releases/2011/04/110421104506.htm>.
American Friends of Tel Aviv University. (2011, April 22). Athletes at risk: New, inexpensive test for 'sudden death syndrome'. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/04/110421104506.htm
American Friends of Tel Aviv University. "Athletes at risk: New, inexpensive test for 'sudden death syndrome'." ScienceDaily. www.sciencedaily.com/releases/2011/04/110421104506.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins